Published in J Pharm Sci on August 01, 1972
Bioequivalence; its history, practice, and future. AAPS J (2009) 1.30
Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol (2001) 1.06
Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol. Br J Clin Pharmacol (1981) 0.92
Establishing equivalence or non-inferiority in clinical trials: part 20 of a series on evaluation of scientific publications. Dtsch Arztebl Int (2012) 0.89
Generics, chemisimilars and biosimilars: is clinical testing fit for purpose? Br J Clin Pharmacol (2013) 0.87
Influence of food on the absorption of metoprolol administered as an Oros drug delivery system to man. Br J Clin Pharmacol (1985) 0.82
Comment on: Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe by Johnston et al. Br J Clin Pharmacol (2011) 0.78
On the definition and interpretation of voice selective activation in the temporal cortex. Front Hum Neurosci (2014) 0.76
Bioavailability limits. Can Med Assoc J (1972) 0.75
Relative bioavailability of commercial ampicillin formulations in man. Can Med Assoc J (1973) 0.75
Pharmacokinetics and Pharmacodynamics of Follicle-Stimulating Hormone in Healthy Women Receiving Single and Multiple Doses of Highly Purified Human Menotrophin and Urofollitrophin. Clin Drug Investig (2016) 0.75
Likelihood approach for evaluating bioequivalence of highly variable drugs. Pharm Stat (2014) 0.75
Symmetrical confidence intervals for bioequivalence trials. Biometrics (1976) 1.78
Bioavailability of cimetidine in man. Gastroenterology (1978) 1.61
Time integral of drug concentration in the central (plasma) compartment. J Pharm Sci (1970) 1.07
The use of balanced incomplete block designs in comparative bioavailability trails. Biometrics (1974) 0.97
Problems associated with analysis of pharmacokinetic models. J Pharm Sci (1971) 0.90
Statistical aspects of comparative bioavailability trials. Biometrics (1979) 0.82
Use of statistical methods in evaluation of in vivo performance of dosage forms. J Pharm Sci (1973) 0.78
The bladderless dog: a new animal model for use in experimental xenobiology. Drug Metab Rev (1981) 0.75
Magnesium lauryl sulfate--soluble lubricant. J Pharm Sci (1972) 0.75
Steady-state lithium blood level fluctuations in man following administration of a lithium carbonate conventional and controlled-release dosage form. J Clin Pharmacol (1981) 0.75
A clinical evaluation of a new concentrated antacid. II. Safety and efficacy in duodenal ulcer patients. J Clin Pharmacol New Drugs (1971) 0.75
Letter: Demonstration of claimed "controlled-release" properties of a drug formulation. J Pharm Sci (1975) 0.75
A pharmacokinetic analysis of lithium carbonate absorption from several formulations in man. J Clin Pharmacol New Drugs (1971) 0.75
Statistical problems in interpreting comparative bioavailability trials. Int J Clin Pharmacol Biopharm (1975) 0.75
A clinical evaluation of a new concentrated antacid. I. Effects on gastric pH. J Clin Pharmacol New Drugs (1971) 0.75
Proceedings: Statistical considerations in the planning and analysis of pharmacokinetic experiments. Acta Pharm Suec (1974) 0.75
Statistical implications in generic equivalents. Psychopharmacol Bull (1976) 0.75